Celltrion Presents Favorable Outcomes for Subcutaneous Infliximab at ACG Meeting
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Celltrion announced that analyses of ZYMFENTRA® will be presented at the American College of Gastroenterology Annual Scientific Meeting. The studies compared subcutaneous (SC) and intravenous (IV) infliximab in patients with ileum-dominant Crohn's disease. The findings indicated significantly higher rates of clinical remission and improved endoscopic outcomes with SC versus IV infliximab in this patient group.
From prnewswire.com
Why it matters
The presentation included a pooled analysis comparing SC and IV infliximab, as well as a post hoc analysis assessing the impact of prior anti-drug antibody status on outcomes following SC infliximab initiation. These results provide evidence regarding the efficacy of different administration routes for inflammatory bowel disease treatments.
From prnewswire.com
Who's involved
- CelltrionSouth Korean biopharmaceutical company presenting scientific findings on ZYMFENTRA®
- American College of GastroenterologyMedical association hosting the scientific meeting where Celltrion presented
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- CelltrionSpeculative
The positive clinical findings could support future sales and market adoption of ZYMFENTRA®.
Keep exploring
The entities involved
-
Celltrion
South Korean biopharmaceutical company
Nothing else this week.
-
American College of Gastroenterology
medical association of gastroenterologists